Sustained Contraction of Vascular Smooth Muscle: Calcium Influx or C-kinase Activation?
Overview
Authors
Affiliations
We have investigated the relative contributions of Ca++ influx and C-kinase activation to the sustained contraction of smooth muscle of rabbit aorta. In physiological salt solution (PSS), the alpha adrenergic agonist, phenylephrine (PhE), induced a rapid initial contraction followed by a maintained tonic contraction whereas the C-kinase activator, 12-O-tetradecanoylphorbol-13-acetate (TPA), caused only a slow tonic contractile response. Both PhE- and TPA-induced contractions were accompanied by a significant increase in the unidirectional 45Ca influx. The tonic phase of PhE contraction and the slow contractile response of TPA also were reduced, but not abolished completely in Ca++-free solution containing 2 mM ethylene glycol bis-(beta-aminoethyl ether)-N,N'-tetraacetic acid. In addition, the relatively specific C-kinase inhibitor, H-7 [1-(5-isoquinolinesulfonyl)-2-methylpiperazine], reversibly inhibited the TPA-induced contraction in PSS and almost abolished the TPA response in Ca++-free solution. On the other hand, H-7 caused only partial inhibition (30.2% +/- 4.09, n = 5) of the PhE sustained contraction in PSS and abolished completely the residual PhE maintained response in Ca++-free solution. The H-7 inhibition of the PhE sustained contraction was reversible in both PSS and Ca++-free solution. Furthermore, TPA alone could not maintain the contractile response initiated by a high K+ depolarizing solution upon replacement of the high K+ solution by normal PSS. These findings emphasize the importance of Ca++ influx and suggest only a minor role of C-kinase in maintaining the tonic contraction of vascular smooth muscle.
extract improves age-induced vascular dysfunction.
Majewski M, Klett-Mingo M, Verdasco-Martin C, Otero C, Ferrer M Pharm Biol. 2022; 60(1):627-637.
PMID: 35294322 PMC: 8933018. DOI: 10.1080/13880209.2022.2047209.
Evolving mechanisms of vascular smooth muscle contraction highlight key targets in vascular disease.
Liu Z, Khalil R Biochem Pharmacol. 2018; 153:91-122.
PMID: 29452094 PMC: 5959760. DOI: 10.1016/j.bcp.2018.02.012.
Xia Y, Khalil R Am J Physiol Heart Circ Physiol. 2016; 310(11):H1851-65.
PMID: 27199130 PMC: 4935520. DOI: 10.1152/ajpheart.00876.2015.
Ou M, Dang Y, Mazzuca M, Basile R, Khalil R J Cell Physiol. 2013; 229(4):489-501.
PMID: 24105843 PMC: 3867575. DOI: 10.1002/jcp.24469.
Mazzuca M, Dang Y, Khalil R Br J Pharmacol. 2013; 169(6):1335-51.
PMID: 23646960 PMC: 3831712. DOI: 10.1111/bph.12225.